Ontology highlight
ABSTRACT:
SUBMITTER: Strickler JH
PROVIDER: S-EPMC3793400 | biostudies-other | 2012 Aug
REPOSITORIES: biostudies-other
Strickler John H JH Starodub Alexander N AN Jia Jingquan J Meadows Kellen L KL Nixon Andrew B AB Dellinger Andrew A Morse Michael A MA Uronis Hope E HE Marcom P Kelly PK Zafar S Yousuf SY Haley Sherri T ST Hurwitz Herbert I HI
Cancer chemotherapy and pharmacology 20120629 2
<h4>Purpose</h4>To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus, and panobinostat (LBH-589) when administered in combination to patients with advanced solid tumor malignancies.<h4>Experiment design</h4>Subjects received 10 mg of panobinostat three times weekly, 5 or 10 mg everolimus daily, and bevacizumab at 10 mg/kg every 2 weeks. Dose-limiting toxicities (DLTs) were assessed in cycle 1; toxicity evaluation was closely monitored through ...[more]